Canagliflozin for the treatment of type 2 Diabetes Mellitus
Canagliflozin for the treatment of type 2 Diabetes Mellitus
Country | Agency | Status | Link | Details on adaptation process | Contact information |
---|---|---|---|---|---|
Croatia | AAZ | 2014 | Link to the summary | Summary of information from the report for decision makers and website | Mirjana Huic (Mirjana.Huic@aaz.hr) |
Hungary | NIPN | Used to validate technology developer submission of evidence | NIPN (HUNHTAWP7@ogyei.gov.hu) | ||
Italy | AIFA | Information missing.
For further details, please contact Ingrid Wilbacher: ingrid.wilbacher@hvb.zoverz.at
(WP3 LP) or Agnese Cangini
a.cangini@aifa.gov.it | Agnese Cangini
a.cangini@aifa.gov.it | ||
Luxembourg | CMSS | Used in cross-checking evidence. | Yves Bruch
yves.bruch@secu.lu | ||
Malta | MEH | Used in direct decision-making. | Antonia Formosa
antonia.formosa@gov.mt | ||
Portugal | INFARMED | Used in cross-checking evidence. | João Martins
joao.martins@infarmed.pt | ||
Slovakia | MoH SK | Used in direct decision-making. | Tomas Tesar
tomas.tesar@union.sk | ||
Spain | AETSA | Published July 2015 | Link to report In Spanish | The EUnetHTA assessment was adapted, i.e. systematic extraction of relevant HTA information from an existing joint assessment. | Teresa Molina Lopez
mariat.molina.lopez@juntadeandalucia.es |
Spain | MSSSI | Published June 2015 | Link to report In Spanish | National Adaptation | Celia Juarez Rojo
cjuarex@msssi.es |
Sweden | TLV | Used in cross-checking evidence. | Johan Ponten
johan.ponten@tlv.se |